Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Hemab Therapeutics
Biotech
Seaport CEO's 'rationale behind going public' via $255M IPO
"We want to develop those programs as far as we can ourselves,” Seaport CEO Daphne Zohar told Fierce.
James Waldron
May 1, 2026 12:30pm
Seaport, Hemab chart courses for $180M IPOs this week
Apr 27, 2026 12:29pm
Seaport, Hemab prepare IPOs to fund depression, clotting drugs
Apr 13, 2026 7:12am
Hemab raises $157M series C for rare bleeding disorder goals
Oct 27, 2025 6:00am
Merck KGaA lands new R&D chief—Chutes & Ladders
Sep 5, 2025 8:30am
Apellis COO stepping down to take first CEO job—Chutes & Ladders
Jan 17, 2025 8:30am
